Together we will beat cancer

Donate

Immunotherapy treatment fast tracked to treat lung cancer patients in England

Hope for patients with early-stage lung cancer as new treatment approved for use on NHS England.

Read More

New breast and lung cancer treatments approved in Scotland

3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer.

Read More

New lung cancer treatment combo approved on NHS in England

A new treatment for some people with a type of non small cell lung cancer (NSCLC) will now be routinely available on the NHS in England, following its approval by the National Institute of Health and Care Excellence (NICE).

Read More

Prising open the trap: Getting to grips with targeted cancer drug resistance

Cancer Research UK-funded scientists are using innovative techniques to understand how resistance to a targeted cancer drug is unfolding.

Read More

Let’s get to the bottom of it – 7 common cancer myths, unpicked

From 5G to sharks with cancer, we want to set the record straight with 7 commonly asked questions about cancer that are often rooted in misinformation.

Read More

Immunotherapy approved for some people with advanced melanoma in England

The National Institute for Health and Care Excellence has recommended the use of the immunotherapy drug pembrolizumab (Keytruda) for some adults in England with a type of advanced melanoma skin cancer.

Read More

Ovarian, bowel and non-Hodgkin’s lymphoma treatments approved for NHS use in Scotland

Three new treatment options made available for cancer patients in Scotland.

Read More

How will new cancer medicines be approved in the future?

In the last decade, many more cancer drugs have become available compared to what we’ve seen previously. This has led to more cancer treatment options, but it has also led to more uncertainty about drugs’ clinical benefit and cost-effectiveness. How can this be addressed?

Read More

Over 600 people in England set to benefit from innovative lung cancer treatment

More than 600 people in England with a form of lung cancer could benefit from the innovative drug osimertinib (Tagrisso) after its approval by the National Institute for Health and Care Excellence.

Read More

Targeted drug recommended to treat some advanced lung cancer patients

Selpercatinib will expand treatment options available for people with RET fusion positive non small cell lung cancer on the NHS in England.

Read More